NKTR logo

NKTR
Nektar Therapeutics

8,523
Mkt Cap
$1.26B
Volume
736,593.00
52W High
$66.92
52W Low
$6.48
PE Ratio
-6.94
NKTR Fundamentals
Price
$55.11
Prev Close
$60.35
Open
$60.99
50D MA
$57.79
Beta
2.01
Avg. Volume
842,874.74
EPS (Annual)
-$8.68
P/B
12.73
Rev/Employee
$1.61M
Loading...
Loading...
News
all
press releases
Nektar Therapeutics $NKTR Shares Sold by Connor Clark & Lunn Investment Management Ltd.
Connor Clark & Lunn Investment Management Ltd. cut its stake in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 94.2% in the second quarter, according to its most recent disclosure with...
MarketBeat·18h ago
News Placeholder
More News
News Placeholder
Nektar Therapeutics $NKTR Shares Sold by Savant Capital LLC
Savant Capital LLC reduced its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 62.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and...
MarketBeat·2d ago
News Placeholder
Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded Nektar Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday...
MarketBeat·5d ago
News Placeholder
HC Wainwright Analysts Boost Earnings Estimates for NKTR
Nektar Therapeutics (NASDAQ:NKTR - Free Report) - HC Wainwright upped their Q4 2025 EPS estimates for shares of Nektar Therapeutics in a research note issued to investors on Tuesday, November 11th...
MarketBeat·6d ago
News Placeholder
Does Nektar (NKTR) Have the Potential to Rally 62.75% as Wall Street Analysts Expect?
The consensus price target hints at a 62.8% upside potential for Nektar (NKTR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·8d ago
News Placeholder
Simplify Asset Management Inc. Purchases New Holdings in Nektar Therapeutics $NKTR
Simplify Asset Management Inc. bought a new stake in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the...
MarketBeat·9d ago
News Placeholder
Acadian Asset Management LLC Sells 6,880,776 Shares of Nektar Therapeutics $NKTR
Acadian Asset Management LLC trimmed its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 94.2% in the second quarter, according to its most recent filing with the Securities...
MarketBeat·9d ago
News Placeholder
Nektar Therapeutics (NASDAQ:NKTR) Receives Average Rating of "Moderate Buy" from Analysts
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven brokerages that are covering the firm, MarketBeat.com reports. One research...
MarketBeat·11d ago
News Placeholder
Nektar Therapeutics (NASDAQ:NKTR) Announces Earnings Results, Beats Estimates By $1.00 EPS
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.85) EPS for the quarter, beating the consensus estimate...
MarketBeat·11d ago
News Placeholder
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting New Data from REZOLVE-AD Study of Rezpegaldesleukin...
PR Newswire·12d ago

Latest NKTR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.